about
Cancer classification using the Immunoscore: a worldwide task forceCancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateTowards the introduction of the 'Immunoscore' in the classification of malignant tumoursAn immunologic portrait of cancerImmunological battlefield in gastric cancer and role of immunotherapiesTumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Infections and cancer: the "fifty shades of immunity" hypothesis.Cancer Immunoprevention and Public Health.Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.Emerging immunologic biomarkers: setting the (TNM-immune) stage.Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: a retrospective study.Evaluation of cancer immunity in mice.The association of low birth weight with serum C reactive protein in 3-year-old children living in Cuba: A population-based prospective study.Immunological network signatures of cancer progression and survivalSpontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges.Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactionsTumor immunosurveillance in human cancers.The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic: The way aheadDoes Opioid Use Cause Angiogenesis and Metastasis?Sequential metastases of colorectal cancer: Immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments.Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.Cancer develops, progresses and responds to therapies through restricted perturbation of the protein-protein interaction network.Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.Naringenin reduces lung metastasis in a breast cancer resection model.SMC4, which is essentially involved in lung development, is associated with lung adenocarcinoma progressionPretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers.Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer.The prognostic impact of anti-cancer immune response: a novel classification of cancer patients.Immune therapy for ovarian cancer: promise and pitfalls.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment.Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay.Interaction of tumour cells with their microenvironment: ion channels and cell adhesion molecules. A focus on pancreatic cancer.Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer.The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.Galectin-1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread.Prognostic value of immunoscore to identify mortality outcomes in adults with HBV-related primary hepatocellular carcinoma.Targetless T cells in cancer immunotherapy.
P2860
Q21245495-0BE523E2-5BE1-4EBE-97DF-5B4E68CB1289Q26782573-A7745ADB-D576-4CEC-BE02-A20ABEFAF024Q27026489-0A0C2E0B-D7EA-4339-82AA-8F7B0706BBEBQ27028000-626FA738-04C2-4606-91C7-AA4129FA8BCFQ28071836-725212C9-9FFC-4F4D-8DCF-B713C41493D9Q28116224-34FE9F4B-42BE-483B-94BC-04790B2E580FQ33555975-06FF94F0-983F-4586-A121-136612AC2526Q33646584-99F53B1F-995D-4AE3-BCA2-FAA680C5520AQ33659224-1C72BA67-A678-432B-BA5E-1672EC87E39DQ33677916-9743E74B-145F-4116-B371-E9669BDC5E6FQ33755824-7BBBC981-0205-4E99-A865-9AEAADF38F18Q33797669-F34095E5-18A6-46EA-AB6D-B9AD1DF244F5Q33834154-C1D1A0D9-0D28-4382-94B4-0DED4D2977B8Q33858844-49AD7BFE-BB91-4D9E-9D20-0B39B29FAE6AQ34151620-7735341D-F221-42DB-A1D9-7EAC8B8C0A36Q34477550-DC4A0F71-85D4-4AA4-A7F0-C00DAB64C986Q34601529-6526E8BA-07EA-40B5-8BBD-4E7C831E21CAQ36038391-2189ABD7-E44B-4391-AFAE-A490B7FFE25AQ36062073-A3DB342B-ECC8-44F0-AF3F-314BDF9E3B7BQ36194809-C663F849-8209-4596-A386-69AA7CDFE789Q36261405-FF7B4C43-937A-437C-8458-46E619961B58Q36322760-47EBF986-B247-463A-820F-8DDBCAB2670EQ36424477-123C850E-B750-4423-A120-D0F1C0F6040DQ36715205-5C570CB8-E579-4588-B731-A0CE30A8DF7EQ36922668-24D3D4A5-9A99-4119-84CE-0F1F2718E071Q37298676-0509E55B-E071-441E-98C2-E34796C42B20Q37551110-8C52F770-CCD8-4AEF-946A-D3A98F1D99DCQ37687671-E27A7D55-C0ED-4075-A24D-DF3D0AD18146Q37861024-AE16E4B3-9D54-4DC5-8D34-AD6A3996A6C0Q37873928-B7561056-0EA7-4605-8FD1-E0F789C4BC05Q38025696-256F6DEC-2A52-4762-9FB8-785E542BAA5BQ38031760-8DCEB1D0-CCF4-4846-AA73-8D8FE2E8699AQ38160401-C0B84225-F0ED-4904-8735-730F8DE50E25Q38184985-7113C18C-5DDF-4B9E-8DD3-8BEB46844B6FQ39313889-8CA05E6E-699B-4ED8-83DE-D7F961904852Q39486461-B2F11B66-910A-4C9F-9A99-0FAD1B2F9C42Q39970530-AEFCC18C-1A3A-47A1-A797-8172FD5D0BEAQ40115919-E1A90455-5BAD-41B3-8604-14B9414A98DEQ40227043-81A8CFCF-3AFB-4D02-BA58-0051266AA42EQ40322821-FCF565F7-C1F1-4B1D-90C5-1744A53DD10D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Natural immunity to cancer in humans.
@en
Natural immunity to cancer in humans.
@nl
type
label
Natural immunity to cancer in humans.
@en
Natural immunity to cancer in humans.
@nl
prefLabel
Natural immunity to cancer in humans.
@en
Natural immunity to cancer in humans.
@nl
P2093
P50
P1476
Natural immunity to cancer in humans.
@en
P2093
Bernhard Mlecnik
Franck Pagès
Gabriela Bindea
Wolf-Herman Fridman
P304
P356
10.1016/J.COI.2010.02.006
P577
2010-03-06T00:00:00Z